Johnson & Johnson presents new IMAAVY data in generalized myasthenia gravis
Two-year long-term extension data show sustained disease control, improved daily function and muscle strength, and lower corticosteroid use in anti-AChR+ adolescents.
GetSignal Johnson & Johnson JNJ
Johnson & Johnson announced new IMAAVY (nipocalimab-aahu) findings for generalized myasthenia gravis on September 29, 2026, across 15 novel abstracts to be presented at two medical meetings.
A retrospective survey of adults found fluctuating symptom control was a top driver for discontinuing prior advanced treatment, and most patients' outcomes improved after switching to IMAAVY.
Key facts
- Date
- September 29, 2026
- Drug
- IMAAVY (nipocalimab-aahu)
- Condition
- Generalized myasthenia gravis (gMG)
- Novel abstracts
- 15
Source: The company's release on PR Newswire, September 29, 2026.
Written by GetSignal with AI from the company's press release.
Not investment advice.
